Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries

Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China. Different from hepatocellular carcinoma in China, hepatocellular carcinoma in Western countries is caused by hepatitis C an...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2023-06, Vol.70, p.102362-102362, Article 102362
Main Authors: He, MinKe, Liu, ShuYue, Lai, ZhiCheng, Du, ZeFeng, Li, QiJiong, Xu, Li, Kan, Anna, Shen, JianXian, Shi, Ming
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - pathology
Fluorouracil - therapeutic use
Humans
Liver Neoplasms - drug therapy
Liver Neoplasms - pathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China. Different from hepatocellular carcinoma in China, hepatocellular carcinoma in Western countries is caused by hepatitis C and alcoholic liver disease, and is often diagnosed at an early stage, when the tumor is small or the thrombus is not serious. Although there are no reports of FOLFOX-HAIC efficacy for hepatocellular carcinoma in Western countries, FOLFOX-HAIC can be used in patients with large tumors (> 5 cm) (or T3 by TNM stage), and rich blood supply.
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2023.102362